diabetes type 2 Flashcards
what is type 2 diabetes
combo of insulin resistance and b-cell failure resulting hyperglycaemia
insulin production not enough to overcome insulin resistance
relative deficiency
not usually DKA
stages of development of T2D
normal
fasting glucose levels ≤6mmol/L
OGTT <7.7mmol/L
HbA1C <42mmol/mol
intermediate state
impaired fasting glycaemia
impaired glucose tolerance
pre-diabetic/non-diabetic hyperglycaemia
T2D
fasting glucose levels ≥7mmol/L
OGTT ≥11mmol/L
HbA1C ≥48mmol/mol
what happens in long-duration type 2 diabetes
beta-cell failure -> complete insulin deficiency
Usually on insulin at this point stopping would risk ketoacidosis
what happens to glucose uptake in skeletal muscle and HGO
skeletal muscle - less uptake of glucose
HGP- increased: lower insulin and increased glucagon action
genetic types of T2D
monogenic
polygenic
what is monogenic
Single gene mutation ==> Diabetes (MODY=Maturity-onset diabetes of the young)
‘Born with it, always going to develop diabetes
what is polygenic
Polymorphisms increasing risk of diabetes
‘Not born with it but high risk and may develop later depending on other factors’
how to assess GWAS in T2D
2 groups- people with AND without T2D
nucleotide changes present in T2D but not control group
assess effect size
SNP- the one that stood out/individual vs group risk
TCF7L2
Each individual SNP has only a mild effect on risk
Cumulative effect of all SNPs have a bigger effect
T2D diagnosis
First line test for diagnosis is HbA1c.
1x HbA1c >=48mmol/L with symptoms
Or
2x HbA1c >=48 mmol/mol if aysymptomatic
difference between T1D/TD2
T2D: Insufficient insulin (NOT ABSENT) for prevention of hyperglycemia but sufficient insulin for suppression of lipolysis and ketogenesis.
hyperosmolar hyperglycaemic state
Presents commonly with renal failure.
often following Infection/MI
what is the GI incretin effect
The relative increase in insulin in response to oral glucose compared to IV glucose.
Relevant for treatment T2dm.
GLP-1 agonist
name
how to administer
effects
Liraglutide, Semaglutide
Injectable –daily, weekly
Decrease [glucagon]
Decrease [glucose]
Weight loss
Gliptins (DPPG-4 inhibitor)
effects
Increase half life of exogenous GLP-1
Increase [GLP-1]
Decrease [glucagon]
Decrease [glucose]
Neutral on weight